Weekly biological variation of serum biochemistry analytes and fibroblast growth factor 23 in healthy cats and cats with chronic kidney disease
Journal of Small Animal Practice · 2025
DOI: 10.1111/jsap.13892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Small Animal Practice, 2025. Verfasst von S Summers und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Cat Diseases, Fibroblast Growth Factors. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: IDEXX Laboratories, Inc..
Abstract (Originalsprache)
Objective
The objective of the study was to determine the biological variation of select serum biochemistry analytes and fibroblast growth factor 23 in both clinically healthy cats and cats with chronic kidney disease.
Methods
Eleven healthy cats and seven cats with chronic kidney disease International Renal Interest Society Stages 2 and 3 were included. Sera were collected once a week for 6 weeks and frozen for batch analysis in duplicate. Blood urea nitrogen, total carbon dioxide, creatinine, magnesium, phosphate, potassium, symmetric dimethylarginine, total calcium and fibroblast growth factor 23 were measured. Restricted maximum likelihood estimations were used to determine the coefficients of variation, and the inverse indices of individuality and reference change values were calculated.
Results
No analytes had low individuality. Biochemistry analytes had either intermediate or high individuality in healthy cats and cats with chronic kidney disease. Fibroblast growth factor 23 had high individuality in healthy cats and cats with chronic kidney disease. The reference change values for analytes was overall similar between healthy cats and cats with chronic kidney disease, including the reference change values for creatinine (19.8% and 18.4%, respectively), symmetric dimethylarginine (35.2% and 35.5%, respectively) and fibroblast growth factor 23 (60.0% and 75.5%, respectively). Clinical Significance Biological variation estimates for each analyte were similar between healthy cats and those with chronic kidney disease. All analytes had intermediate to high individuality in cats with chronic kidney disease; thus, determining a cat’s baseline and applying the reference change values to subsequent measurements may enhance the detection of clinically relevant changes that could be missed when using population‐based reference intervals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA.
- IDEXX Laboratories, Inc., Westbrook, Maine, USA.
ORCID-Profile: S Summers, H T Michael
Förderung
- IDEXX Laboratories, Inc.
Zitieren
APA
Summers, S., Szlosek, D., Michael, H. T., & Mack, R. (2025). Weekly biological variation of serum biochemistry analytes and fibroblast growth factor 23 in healthy cats and cats with chronic kidney disease. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13892
Vancouver
Summers S, Szlosek D, Michael HT, Mack R. Weekly biological variation of serum biochemistry analytes and fibroblast growth factor 23 in healthy cats and cats with chronic kidney disease. Journal of Small Animal Practice. 2025. doi:10.1111/jsap.13892
BibTeX
@article{Summers2025,
author = {Summers, S and Szlosek, D and Michael, H T and Mack, R},
title = {Weekly biological variation of serum biochemistry analytes and fibroblast growth factor 23 in healthy cats and cats with chronic kidney disease},
journal = {Journal of Small Animal Practice},
year = {2025},
doi = {10.1111/jsap.13892}
}
EUVIMED